RxDoctor Payments Data

Zhanna Kovaleva, APRN

Family · San Antonio, TXNPI 1942898424

Payments from drug & device makers

$2,744in general payments, 2019–2025

Across 26 payments — averaging $105.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$766
  • AstraZeneca$639
  • Biotronik Inc.$404
  • Amgen$250
  • Merck$193
  • Alnylam Pharmaceuticals Inc.$162
  • plus $330 from 3 others

What the payments were for

  • Travel & lodging$26110%
  • Food & beverage$2,30584%
  • Education$1797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,744 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$39,794
Medicare patients
247
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$170,185
XareltoRivaroxaban46$53,554
MultaqDronedarone Hcl18$23,461
FarxigaDapagliflozin Propanediol18$20,992
EntrestoSacubitril/Valsartan18$15,570
JardianceEmpagliflozin14$13,217
Repatha SureclickEvolocumab12$7,619
Dofetilide26$2,498
Flecainide Acetate54$2,439
Metoprolol Succinate195$2,254
Atorvastatin Calcium154$1,664
Ezetimibe91$909
SotalolSotalol Hcl35$760
Losartan Potassium84$747
Ranolazine ErRanolazine12$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$170,185159 claims
Sanofi-aventis U.S. LLCMultaq$121$23,46118 claims
AstraZenecaFarxiga$639$20,99218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →